Which of the following sulfonylureas cannot be used in patients with kidney failure?
Sulfonylureas work by stimulating insulin release from pancreatic beta cells. Common ones include glyburide, glipizide, glimepiride, and gliclazide. Now, their metabolism and excretion are key here.
Glyburide is known to be metabolized by the liver and excreted by the kidneys. Since it's primarily renally excreted, in kidney failure, it can accumulate, leading to prolonged hypoglycemia. That's dangerous. Glipizide and glimepiride have some renal excretion but are considered safer in renal impairment because they have shorter half-lives and are less likely to accumulate. Gliclazide is metabolized and excreted through both liver and kidneys, but maybe it's less dependent on renal function.
The question is about which one is contraindicated. Glyburide is the classic example here. The other options might be glipizide, glimepiride, and gliclazide. So the correct answer would be glyburide.
Wait, but I should check if there are any nuances. For example, some guidelines might say that glipizide can be used with caution in mild renal impairment, but glyburide is definitely contraindicated in severe renal failure. Also, newer sulfonylureas like glimepiride have better profiles.
So the incorrect options would be the other sulfonylureas. The clinical pearl here is that glyburide's renal excretion makes it unsuitable for kidney failure. Students should remember that glyburide is the "old" one with higher risk of hypoglycemia in renal issues.
**Core Concept**
Sulfonylureas stimulate insulin release by binding to ATP-sensitive potassium channels in pancreatic beta cells. Renal excretion and metabolism determine their safety in kidney failure, as impaired clearance increases hypoglycemia risk. Glyburide (glibenclamide) is renally excreted and has a long half-life, making it contraindicated in renal impairment.
**Why the Correct Answer is Right**
Glyburide is primarily excreted unchanged by the kidneys. In renal failure, it accumulates, prolonging hypoglycemia and increasing mortality risk. Its metabolism does not significantly involve hepatic pathways, unlike newer agents like glimepiride, which are safer in renal dysfunction due to hepatic metabolism and shorter duration of action.
**Why Each Wrong Option is Incorrect**
**Option A:** Glipizide is metabolized by the liver and excreted via bile, with minimal renal excretion, making it safer in mild-to-moderate renal impairment.
**Option B:** Glimepiride has hepatic metabolism and dual excretion (bile and kidneys), reducing hypoglycemia risk in renal failure compared to glyburide.
**Option C:** Gliclazide is metabolized to inactive compounds and excreted in urine; its active metabolite has a short half-life, allowing cautious use in renal dysfunction.
**Clinical Pearl / High-Yield Fact**